Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a longer time without tumor progression in response to standard treatment, according to a new study ...
SurvivorNet on MSN
For high-risk lymphoma, adding targeted drugs tafasitamab and lenalidomide to standard treatment keeps cancer away for longer
The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy ...
Add Yahoo as a preferred source to see more of our stories on Google. A novel approach to organ transplantation allowed patients to wean off anti-rejection drugs after two years, according to the ...
Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a longer time without tumour progression in response to standard treatment according to a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results